StockNews.AI
OM
StockNews.AI
194 days

Kuehn Law Encourages Investors of Outset Medical, Inc. to Contact Law Firm

1. Kuehn Law investigates Outset Medical for potential fiduciary breaches by insiders. 2. The Tablo products were allegedly misrepresented regarding FDA approval and indications. 3. Insiders may have caused negative impacts on revenue growth and credibility. 4. Shareholders are encouraged to participate in litigation efforts for protection.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit suggests serious issues with compliance and future operations, similar to past cases like Theranos affecting investor confidence.

How important is it?

The investigation could lead to significant financial repercussions, making it crucial for current shareholders.

Why Short Term?

Immediate legal implications may impact stock price rapidly, reminiscent of recent cases with swift declines.

Related Companies

OM
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Outset Medical, Inc. (NASDAQ: OM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Outset insiders caused the company to misrepresent or fail to disclose that (1) the Tablo products were marketed for continuous renal replacement therapy, which is not one of the indications approved by the FDA; (2) that, as a result, Outset Medical was reasonably likely to submit an additional 510(k) application for the Tablo products; (3) that there was a substantial risk that the Company would cease sales of the Tablo products pending FDA approval of additional indications; (4) that Outset Medical lacked the sales team and process to execute on the ramp of Tablo sales; (5) that, as a result of the foregoing, the Company’s revenue growth would be adversely impacted; and (6) that, as a result of the foregoing, positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you currently own OM and purchased prior to August 1 2022 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814.  The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   Why Your Participation Matters: As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™   For additional information, please visit Shareholder Derivative Litigation - Kuehn Law. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts:Kuehn Law, PLLCJustin Kuehn, Esq.53 Hill Street, Suite 605 Southampton, NY 11968justin@kuehn.law(833) 672-0814

Related News